Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Arbutus Biopharma Corp
(NQ:
ABUS
)
3.890
+0.080 (+2.10%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
960,311
Open
3.850
Bid (Size)
3.840 (6)
Ask (Size)
3.890 (15)
Prev. Close
3.810
Today's Range
3.835 - 3.930
52wk Range
1.690 - 3.980
Shares Outstanding
99,161,234
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Arbutus Layoffs 2024: What to Know About the Latest ABUS Job Cuts
August 01, 2024
While the Arbutus layoffs represents a major overhaul operationally, the market has responded positively to ABUS stock. Here’s why.
Via
InvestorPlace
Topics
Workforce
Exposures
Layoff
Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 01, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Performance
YTD
+50.19%
+50.19%
1 Month
-0.77%
-0.77%
3 Month
+16.12%
+16.12%
6 Month
+33.22%
+33.22%
1 Year
+91.63%
+91.63%
More News
Read More
Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update
July 18, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
June 06, 2024
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Earnings Scheduled For February 29, 2024
February 29, 2024
Via
Benzinga
Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
June 06, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure
June 05, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Participate in Jefferies Global Healthcare Conference
May 29, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Present Imdusiran Data at EASL Congress 2024
May 22, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value
May 17, 2024
From
Whitefort Capital Management, LP
Via
Business Wire
Arbutus to Participate in Two Upcoming Investor Conferences
May 07, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
ABUS Stock Earnings: Arbutus Biopharma Beats EPS, Misses Revenue for Q1 2024
May 02, 2024
Via
InvestorPlace
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 02, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024
May 02, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
April 18, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
3 Healthcare Stocks Short Sellers Are Prescribing for Trouble
April 05, 2024
Via
InvestorPlace
Arbutus Vs. Moderna Patent Dispute Over Covid-19 Vaccine Gets Response From Judge
April 04, 2024
Via
Benzinga
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Moderna Shares Slip Over Covid Vaccine Patent Dispute, But Chart Signals Potential Rebound Ahead
April 04, 2024
Via
Benzinga
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
April 04, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Stock Soars 20% As It Heads To Trial With Moderna In Covid Vaccine Patent Claim
April 03, 2024
Via
Benzinga
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Arbutus to Participate in Two Upcoming Investor Conferences
March 08, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
February 29, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
February 15, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Arbutus Announces 2024 Corporate Objectives and Provides Financial Update
January 08, 2024
From
Arbutus Biopharma Corporation
Via
GlobeNewswire
Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD
November 09, 2023
From
Barinthus Biotherapeutics
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.